Our study used scRNA-seq to represent a novel investigation into the role of FABP4+C1q+ macrophages in the TME, particularly focusing on their prognostic value in NSCLC patients following neoadjuvant chemoimmunotherapy. Here, FABP4 is linked to non-small cell lung carcinoma.